Updated On: 01 July, 2021 12:00 AM IST | New Delhi | ANI
The CEO of Pune-based SII, Adar Poonawalla, had in March this year said that the trials for 'Covavax', the Covid-19 vaccine developed by US-based vaccine manufacturer Novavax, have begun in India, and added that he is hoping the vaccine launch will take place by September this year

Photo for representational purpose
An expert panel constituted by the government has recommended against granting permission to the Serum Institute of India (SII) to conduct phase two and three clinical trials of Covavax Covid-19 vaccine on children aged between 2-17 years, said sources on Thursday.
According to the sources, the government panel has asked the Institute to complete trials on adults first.